专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

1. 发明授权

US08685450B2 Dual drug dosage forms with improved separation of drugs 有权
标题翻译：具有改善药物分离的双重药物剂型
公开(公告)号：US08685450B2
公开(公告)日：2014-04-01
申请号：US13530631
申请日：2012-06-22
申请人： Jong Lim , John N. Shell , Jenny Louie-Helm
发明人： Jong Lim , John N. Shell , Jenny Louie-Helm
IPC分类号： A61K9/22 , A61K9/24
CPC分类号： A61K31/4415 , A61K9/0065 , A61K9/2018 , A61K9/2027 , A61K9/2031 , A61K9/2054 , A61K9/2077 , A61K9/209 , A61K9/2853 , A61K31/00 , A61K31/155 , A61K31/40 , A61K31/4015 , A61K45/06 , A61K2300/00
摘要： Drug tablets that include a prolonged-release core and an immediate-release layer or shell are prepared with a thin barrier layer of drug-free polymer between the prolonged-release and immediate-release portions of the tablet. The barrier layer is penetrable by gastrointestinal fluid, thereby providing full access of the gastrointestinal fluid to the prolonged-release core, but remains intact during the application of the immediate-release layer, substantially reducing or eliminating any penetration of the immediate-release drug into the prolonged-release portion.
摘要翻译：包含延长释放核心和速释层或壳的药物片剂在片剂的延长释放和速释部分之间用无药物聚合物的薄屏障层制备。阻隔层可被胃肠液渗透，从而使胃肠道液体完全进入延长释放核心，但在施用速释层期间保持完整，从而大大减少或消除了立即释放药物的渗透延长释放部分。

2. 发明申请

US20120263792A1 DUAL DRUG DOSAGE FORMS WITH IMPROVED SEPARATION OF DRUGS 有权
标题翻译：双剂量剂型改进分离药物
公开(公告)号：US20120263792A1
公开(公告)日：2012-10-18
申请号：US13530631
申请日：2012-06-22
申请人： JONG LIM , John N. Shell , Jenny Louie-Helm
发明人： JONG LIM , John N. Shell , Jenny Louie-Helm
IPC分类号： A61K9/00 , A61K9/14 , A61K31/4965 , A61K31/426 , A61K31/4015 , A61K31/18
CPC分类号： A61K31/4415 , A61K9/0065 , A61K9/2018 , A61K9/2027 , A61K9/2031 , A61K9/2054 , A61K9/2077 , A61K9/209 , A61K9/2853 , A61K31/00 , A61K31/155 , A61K31/40 , A61K31/4015 , A61K45/06 , A61K2300/00
摘要： Drug tablets that include a prolonged-release core and an immediate-release layer or shell are prepared with a thin barrier layer of drug-free polymer between the prolonged-release and immediate-release portions of the tablet. The barrier layer is penetrable by gastrointestinal fluid, thereby providing lull access of the gastrointestinal fluid to the prolonged-release core, but remains intact during the application of the immediate-release layer, substantially reducing or eliminating any penetration of the immediate-release drug into the prolonged-release portion.
摘要翻译：包含延长释放核心和速释层或壳的药物片剂在片剂的延长释放和速释部分之间用无药物聚合物的薄屏障层制备。阻隔层可被胃肠道液体穿透，从而使胃肠道液体延伸到延长释放核心，但在施用速释层期间保持完整，从而显着减少或消除了立即释放药物的任何渗透延长释放部分。

3. 发明申请

US20110236485A1 SHELL AND CORE DOSAGE FORM APPROACHING ZERO-ORDER DRUG RELEASE 有权
标题翻译：壳和核心剂量形式进行零售药物释放
公开(公告)号：US20110236485A1
公开(公告)日：2011-09-29
申请号：US13156225
申请日：2011-06-08
申请人： BRET BERNER , Jenny Louie-Helm , Gloria Gusler , John N. Shell
发明人： BRET BERNER , Jenny Louie-Helm , Gloria Gusler , John N. Shell
IPC分类号： A61K9/14 , A61K31/155 , A61P3/10 , A61K31/675 , A61K31/616 , A61P31/00
CPC分类号： A61K9/2866 , A61K9/0002 , A61K9/2027 , A61K9/284 , A61K9/2853 , A61K31/155 , A61K31/472 , A61K31/525 , A61K31/60
摘要： Drugs are formulated as oral dosage forms for controlled release in which the release rate limiting portion is a shell surrounding the drug-containing core. The shell releases drug from the core by permitting diffusion of the drug from the core. The shell also motes gastric retention of the dosage form by swelling upon imbibition of gastric fluid to size that is retained in the stomach during the postprandial or fed mode.
摘要翻译：将药物配制成用于控制释放的口服剂型，其中释放速率限制部分是围绕药物含核心的壳。壳体通过允许药物从核心扩散而释放出核心的药物。该外壳还通过在胃液吸入胃中在餐后或喂食模式下保留在胃中的大小时肿胀而使胃滞留。

4. 发明授权

US07736667B2 Shell-and-core dosage form approaching zero-order drug release 有权
标题翻译：壳和核心剂型接近零级药物释放
公开(公告)号：US07736667B2
公开(公告)日：2010-06-15
申请号：US10213823
申请日：2002-08-07
申请人： Bret Berner , Jenny Louie-Helm , Gloria Gusler , John N. Shell
发明人： Bret Berner , Jenny Louie-Helm , Gloria Gusler , John N. Shell
IPC分类号： A61K9/52 , A61K9/20 , A61K9/22 , A61K9/24 , A61K9/28
CPC分类号： A61K9/2866 , A61K9/0002 , A61K9/2027 , A61K9/284 , A61K9/2853 , A61K31/155 , A61K31/472 , A61K31/525 , A61K31/60
摘要： Drugs are formulated as oral dosage forms for controlled release in which the release rate limiting portion is a shell surrounding the drug-containing core. The shell releases drug from the core by permitting diffusion of the drug from the core. The shell also promotes gastric retention of the dosage form by swelling upon imbibition of gastric fluid to a size that is retained in the stomach during the postprandial or fed mode.
摘要翻译：将药物配制成用于控制释放的口服剂型，其中释放速率限制部分是围绕药物含核心的壳。壳体通过允许药物从核心扩散而释放出核心的药物。外壳还通过在胃液吸收到在餐后或喂食模式下保留在胃中的尺寸时膨胀而促进剂型的胃滞留。

5. 发明授权

US08329215B2 Shell and core dosage form approaching zero-order drug release 有权
标题翻译：壳和核心剂型接近零级药物释放
公开(公告)号：US08329215B2
公开(公告)日：2012-12-11
申请号：US13156225
申请日：2011-06-08
申请人： Bret Berner , Jenny Louie-Helm , Gloria Gusler , John N. Shell
发明人： Bret Berner , Jenny Louie-Helm , Gloria Gusler , John N. Shell
IPC分类号： A61K9/52 , A61K9/20 , A61K9/22 , A61K9/24 , A61K9/28
CPC分类号： A61K9/2866 , A61K9/0002 , A61K9/2027 , A61K9/284 , A61K9/2853 , A61K31/155 , A61K31/472 , A61K31/525 , A61K31/60
摘要： Drugs are formulated as oral dosage forms for controlled release in which the release rate limiting portion is a shell surrounding the drug-containing core. The shell releases drug from the core by permitting diffusion of the drug from the core. The shell also motes gastric retention of the dosage form by swelling upon imbibition of gastric fluid to size that is retained in the stomach during the postprandial or fed mode.
摘要翻译：将药物配制成用于控制释放的口服剂型，其中释放速率限制部分是围绕药物含核心的壳。壳体通过允许药物从核心扩散而释放出核心的药物。该外壳还通过在胃液吸入胃中在餐后或喂食模式下保留在胃中的大小时肿胀而使胃滞留。

6. 发明授权

US08043630B2 Shell-and-core dosage form approaching zero-order drug release 有权
标题翻译：壳和核心剂型接近零级药物释放
公开(公告)号：US08043630B2
公开(公告)日：2011-10-25
申请号：US12770283
申请日：2010-04-29
申请人： Bret Berner , Jenny Louie-Helm , Gloria Gusler , John N. Shell
发明人： Bret Berner , Jenny Louie-Helm , Gloria Gusler , John N. Shell
IPC分类号： A61K9/52 , A61K9/20 , A61K9/22 , A61K9/24 , A61K9/28
CPC分类号： A61K9/2866 , A61K9/0002 , A61K9/2027 , A61K9/284 , A61K9/2853 , A61K31/155 , A61K31/472 , A61K31/525 , A61K31/60
摘要： Drugs are formulated as oral dosage forms for controlled release in which the release rate limiting portion is a shell surrounding the drug-containing core. The shell releases drug from the core by permitting diffusion of the drug from the core. The shell also motes gastric retention of the dosage form by swelling upon imbibition of gastric fluid to size that is retained in the stomach during the postprandial or fed mode.
摘要翻译：将药物配制成用于控制释放的口服剂型，其中释放速率限制部分是围绕药物含核心的壳。壳体通过允许药物从核心扩散而释放出核心的药物。该外壳还通过在胃液吸入胃中在餐后或喂食模式下保留在胃中的大小时肿胀而使胃滞留。

7. 发明申请

US20100272808A1 Shell-and-Core Dosage Form Approaching Zero-Order Drug Release 有权
标题翻译：壳和核心剂量形式接近零级药物释放
公开(公告)号：US20100272808A1
公开(公告)日：2010-10-28
申请号：US12770283
申请日：2010-04-29
申请人： Bret Berner , Jenny Louie-Helm , Gloria Gusler , John N. Shell
发明人： Bret Berner , Jenny Louie-Helm , Gloria Gusler , John N. Shell
IPC分类号： A61K9/10 , A61K31/155 , A61K31/337 , A61K31/401 , A61K31/7048 , A61K31/70 , A61K31/522 , A61K31/341 , A61K31/197 , A61K31/198 , A61K31/135 , A61K31/4365 , A61K38/14 , A61K31/43 , A61K31/545 , A61K31/496 , A61K38/13 , A61K31/7072 , A61P1/00
CPC分类号： A61K9/2866 , A61K9/0002 , A61K9/2027 , A61K9/284 , A61K9/2853 , A61K31/155 , A61K31/472 , A61K31/525 , A61K31/60
摘要： Drugs are formulated as oral dosage forms for controlled release in which the release rate limiting portion is a shell surrounding the drug-containing core. The shell releases drug from the core by permitting diffusion of the drug from the core. The shell also motes gastric retention of the dosage form by swelling upon imbibition of gastric fluid to size that is retained in the stomach during the postprandial or fed mode.
摘要翻译：将药物配制成用于控制释放的口服剂型，其中释放速率限制部分是围绕药物含核心的壳。壳体通过允许药物从核心扩散而释放出核心的药物。该外壳还通过在胃液吸入胃中在餐后或喂食模式下保留在胃中的大小时肿胀而使胃滞留。

8. 发明授权

US06682759B2 Manufacture of oral dosage forms delivering both immediate-release and sustained-release drugs 有权
标题翻译：制备立即释放和持续释放药物的口服剂型
公开(公告)号：US06682759B2
公开(公告)日：2004-01-27
申请号：US10066146
申请日：2002-02-01
申请人： Jong C. Lim , John N. Shell
发明人： Jong C. Lim , John N. Shell
IPC分类号： A61K922
CPC分类号： A61K9/209 , A61K31/155 , A61K2300/00
摘要： A method is disclosed for manufacturing a pharmaceutical tablet for oral administration, the tablet combining both immediate-release and prolonged-release modes of drug delivery and using an immediate-release drug that is either insoluble in water or only sparingly soluble and is present in a very small amount compared to the prolonged-release drug. The method involves the use of particles of the immediate-release drug that are equal to or less than 10 microns in diameter, applied as a layer or coating over a core of the prolonged-release drug, the layer or coating being either the drug particles themselves, applied as an aqueous suspension, or a solid mixture containing the drug in admixture with a material that disintegrates rapidly in gastric fluid. The result in both cases is a high degree of uniformity in the proportions of the immediate-release and prolonged-release drugs, uniformity that is otherwise difficult to achieve in view of the insolubility of the immediate-release drug and its relatively small amount compared to the prolonged-released drug.
摘要翻译：公开了用于制造用于口服给药的药物片剂的方法，所述药片结合药物递送的立即释放和延长释放模式并且使用不溶于水或仅溶于微溶并且存在于与延长释放药物相比非常少量。该方法包括使用直径为等于或小于10微米的速释药物的颗粒，作为延长释放药物的核心上的层或涂层施用，该层或涂层是药物颗粒或者含有药物的固体混合物与在胃液中快速分解的物质混合。两种情况的结果是立即释放和延长释放药物的比例高度均匀，鉴于立即释放药物的不溶性而难以实现的均匀性，并且相对于延长释放的药物。

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式